Literature DB >> 27236145

 Alcoholic hepatitis: How far are we and where are we going?

Verónica Prado1, Joan Caballería2, Víctor Vargas3, Ramón Bataller4, José Altamirano5.   

Abstract

The burden of alcoholic liver disease continues to be a major public health problem worldwide. The spectrum of disease ranges from fatty liver to cirrhosis and hepatocellular carcinoma. Alcoholic hepatitis (AH) is a type of acute-on-chronic liver failure and the most severe form of alcoholic liver disease. Severe AH carries a poor short-term prognosis and its management is still challenging, with scarce advances in the last decades. Corticosteroids are still the first line of therapy in severe cases. Unfortunately, many patients do not respond and novel targeted therapies are urgently needed. Liver transplantation has shown extraordinary results in non-responders to corticosteroids however; its applicability is very low. This review summarizes the epidemiology, natural history, risk factors and pathogenesis of alcoholic liver disease with special focus on the latest advances in prognostic stratification and therapy of patients with alcoholic hepatitis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27236145

Source DB:  PubMed          Journal:  Ann Hepatol        ISSN: 1665-2681            Impact factor:   2.400


  6 in total

1.  Histopathological and Molecular Signatures of a Mouse Model of Acute-on-Chronic Alcoholic Liver Injury Demonstrate Concordance With Human Alcoholic Hepatitis.

Authors:  Shinji Furuya; Joseph A Cichocki; Kranti Konganti; Kostiantyn Dreval; Takeki Uehara; Yuuki Katou; Hisataka Fukushima; Hiroshi Kono; Igor P Pogribny; Josepmaria Argemi; Ramon Bataller; Ivan Rusyn
Journal:  Toxicol Sci       Date:  2019-08-01       Impact factor: 4.849

2.  The MELD Score Is Superior to the Maddrey Discriminant Function Score to Predict Short-Term Mortality in Alcohol-Associated Hepatitis: A Global Study.

Authors:  D Morales-Arráez; M Ventura-Cots; J Altamirano; J G Abraldes; M Cruz-Lemini; M R Thursz; S R Atkinson; S K Sarin; W Kim; R Chavez-Araujo; M F Higuera-de la Tijera; A K Singal; V H Shah; P S Kamath; A Duarte-Rojo; E A Charles; V Vargas; M Jager; P E Rautou; D Rincon; F Zamarripa; J C Restrepo-Gutiérrez; A Torre; M R Lucey; J P Arab; P Mathurin; A Louvet; G García-Tsao; J A González; E C Verna; R S Brown; J Argemi; C Fernández-Carrillo; A Clemente; E Alvarado-Tapias; E Forrest; M Allison; R Bataller
Journal:  Am J Gastroenterol       Date:  2022-02-01       Impact factor: 12.045

Review 3.  Emerging Roles of Impaired Autophagy in Fatty Liver Disease and Hepatocellular Carcinoma.

Authors:  Suryakant Niture; Minghui Lin; Leslimar Rios-Colon; Qi Qi; John T Moore; Deepak Kumar
Journal:  Int J Hepatol       Date:  2021-04-22

4.  Impact of alcohol abstinence on survival after hepatic resection for hepatocellular carcinoma in patients with alcohol-related liver disease.

Authors:  Daisuke Shirai; Hiroji Shinkawa; Shigekazu Takemura; Shogo Tanaka; Ryosuke Amano; Kenjiro Kimura; Masahiko Kinoshita; Norifumi Kawada; Shoji Kubo
Journal:  Ann Med Surg (Lond)       Date:  2021-07-29

Review 5.  Management of Alcohol-Related Liver Disease and Its Complications.

Authors:  Joaquín Cabezas
Journal:  Clin Drug Investig       Date:  2022-04-25       Impact factor: 3.580

6.  A Novel Mouse Model of Acute-on-Chronic Cholestatic Alcoholic Liver Disease: A Systems Biology Comparison With Human Alcoholic Hepatitis.

Authors:  Shinji Furuya; Josepmaria Argemi; Takeki Uehara; Yuuki Katou; Derrick E Fouts; Bernd Schnabl; Laurent Dubuquoy; Abha Belorkar; Rajanikanth Vadigepalli; Hiroshi Kono; Ramon Bataller; Ivan Rusyn
Journal:  Alcohol Clin Exp Res       Date:  2019-11-28       Impact factor: 3.928

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.